Skip to main content

Advertisement

Table 5 Association between CD30 expression and clinicopathologic features of patients with extranodal natural killer/T-cell lymphoma, nasal type

From: CD30 expression in extranodal natural killer/T-cell lymphoma, nasal type among 622 cases of mature T-cell and natural killer-cell lymphoma at a single institution in South China

Variable CD30 expression [cases (%)] P value
Positive Negative
Total 43 48  
Age (years)    0.508
 ≤60 37 (40.6) 44 (48.4)  
 >60 6 (6.6) 4 (4.4)  
Sex    0.675
 Male 33 (36.3) 35 (38.5)  
 Female 10 (10.9) 13 (14.3)  
B symptoms    0.627
 Yes 21 (23.1) 21 (23.1)  
 No 22 (24.1) 27 (29.7)  
Ki-67 index    0.060
 ≤50 14 (15.4) 25 (27.5)  
 >50 29 (31.8) 23 (25.3)  
Primary site    0.720
 Upper aerodigestive tract 37 (40.6) 40 (44.0)  
 Others 6 (6.6) 8 (8.8)  
Ann-Arbor stage    0.080
 I/II 37 (40.6) 34 (37.4)  
 III/IV 6 (6.6) 14 (15.4)  
LDH level    0.894
 Elevated 12 (13.2) 14 (15.4)  
 Normal 31 (34.0) 34 (37.4)  
Therapeutic modality    0.230
 Chemotherapy alone 10 (10.9) 19 (20.9)  
 Chemoradiotherapy 31 (34.0) 27 (29.7)  
 Radiotherapy alone 1 (1.1) 1 (1.1)  
 Chemotherapy plus surgery 1 (1.1) 0 (0.0)  
 Unavailable 0 (0.0) 1 (1.1)  
EBV-DNA status    0.602
 Positive 19 (20.9) 20 (22.0)  
 Negative 18 (19.8) 24 (26.3)  
 Unavailable 6 (6.6) 4 (4.4)  
Relapse    0.657
 Yes 19 (20.9) 19 (20.9)  
 No 24 (26.3) 29 (31.9)  
  1. LDH lactate dehydrogenase, EBV Epstein-Barr virus